🚀 Apply for £10k+ grants with our Startup Launch Kit
shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    PAR-21-233

    National Institutes of Health

    Opening date 23 Apr 2021, 12:00AM

    Closing date 5 Apr 2024, 12:00AM

    Funding Opportunity Number: PAR-21-233

    Opportunity Category: Discretionary

    CFDA Number(s): 93.121 -- Oral Diseases and Disorders Research,93.213 -- Research and Training in Complementary and Integrative Health,93.242 -- Mental Health Research Grants,93.273 -- Alcohol Research Programs,93.279 -- Drug Abuse and Addiction Research Programs,93.286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health,93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders,93.865 -- Child Health and Human Development Extramural Research,93.866 -- Aging Research,93.867 -- Vision Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Apr 23, 2021 12:00:00 AM EDT

    Closing Date: Apr 05, 2024 12:00:00 AM EDT

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: Small businesses

    Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

    Agency Name: National Institutes of Health

    Description:

    The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

    Grantor Contact Information: NIH OER Webmaster grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept